Cohesion Technologies Launches Web Site.

PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 6, 1998--Cohesion Technologies (NASDAQ NM:CSON) today announced the launch of its corporate web site, www.cohesiontech.com. This site is designed to describe the ongoing development of Cohesion Technologies and its products and to provide the medical and investment communities as well as the media with 24-hour access to company news and information. The site includes key textual and graphic material to assist in educating visitors on the company and its products.

The new web site offers the public the opportunity to learn about Cohesion's lead products as well as to gain an understanding of the underlying scientific properties involved in these technologies. A listing of upcoming medical conferences at which the company will be exhibiting is also included. The site allows visitors to look up the current company share price and historical financial information through links to Yahoo Finance and the SEC's Edgar Database. Also included is information about career opportunities, the Cohesion Board of Directors and the senior management team.

Cohesion is focused on developing and commercializing innovative surgical biodevices, including resorbable surgical hemostats and surgical sealants for tissue repair and regeneration. CoStasis(tm) Surgical Hemostat, the company's lead product, recently received the CE Mark in Europe and is in a pivotal clinical study in the U.S. for the treatment of diffuse bleeding in cardiothoracic, hepatic, general, and orthopedic surgical procedures. CoSeal(tm) Surgical Sealant, the company's second product candidate, is being designed to prevent leakage of blood in cardiovascular and vascular surgeries. CoSeal is currently in pre-clinical development.

Cohesion Technologies is developing products for the estimated $1.3 billion worldwide surgical hemostasis and sealant markets. Cohesion Technologies' press releases can be accessed on the company's homepage at http://www.cohesiontech.com.